

From the LipidSpin Editor

1. This literary creation has led to an essential misconception. For Hippocrates, even if food was closely linked to health and disease, the concept of food was not confused with that of medication. Cardenas D, Let not thy food be confused with thy medicine: The Hippocratic misquotation. *Clinical Nutrition e-SPEN*;2013;8(6),e260–e262. <http://dx.doi.org/10.1016/j.clnme.2013.10.002>
2. <https://health.gov/dietaryguidelines/2015/guidelines/>

Clinical Feature

1. McSweeney JC, Rosenfeld AG, Abel WM, et al. Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association *Circulation*. 2016;133:1302-31.
2. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident CHD in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia*. 2014;57:1542-1551.
3. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement. *J Clin Endocrinol Metab*. 2010;95:2038-49.
4. Tanz LJ, Stuart JJ, Williams PL, et al. Preterm delivery and maternal cardiovascular disease in young and middle-age adult women. *Circulation*. 2017;135:578-589.
5. Goueslard K, Cottenet J, Mariet A-S, et al. Early cardiovascular events in women with a history of gestational diabetes mellitus. *Cardiovasc Diabetol*. 2016;15:15.
6. Mongraw-Chaffin ML, Cirillo PM, Cohn BA: Preeclampsia and cardiovascular disease death: prospective evidence from the Child Health and Development Studies Cohort. *Hypertension*. 2010;56:166-171.
7. Lykke JA, Langhoff Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity. *Hypertension*. 2009;53:944-951.
8. Dayan N, Filion IC, Okano M, et al. Cardiovascular risk following fertility therapy: systematic review and meta-analysis. *J Am Coll Cardiol*. 2017;70:1203-1213.
9. Libby P, Ridker PM, Hansson GK: Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol*. 2009;54:2129-2138
10. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of MI and angina in women with SLE: Comparison with the Framingham Study. *Am J Epidemiol*. 1997;145:408-415.
11. Corrales A, Dessein PH, Tsang L, et al. Carotid artery plaque in women with RA and low estimated cardiovascular disease risk: a cross-sectional study. *Arthritis Research and Therapy*. 2015;17:55.
12. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013;368:987-998.
13. Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcium in low-risk women: a meta-analysis. *JAMA*. 2016;316:2126-2134.
14. Cardiology. *J Am Coll Cardiol*. 2012;60(25 Suppl):S1-49.
15. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. *Arch Intern Med*. 2008;168(20):2245-2253.
16. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low-density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. *J Lipid Res*. 1994;35(5):779-792.
17. Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. *Maturitas*. 2015;81(1):62-68.
18. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. *J Intern Med*. 2013;273(1):6-30.
19. Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res*. 2016;57(11):1953-1975.
20. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA*. 2009;302(4):412-423.
21. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA*. 2009;301(22):2331-2339.
22. Clarke R, Pedersen JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. 2009;361(26):2518-2528.
23. Emdin CA, Khera AV, Natarajan P, et al. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. *J Am Coll Cardiol*. 2016;68(25):2761-2772.
24. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Thromb Vasc Biol*. 1997;17(2):239-245.
25. Anagnostis P, Galanis P, Chatzistergiou V, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. *Maturitas*. 2017;99:27-36.
26. Anagnostis P, Karras S, Lambrinoukaki I, Stevenson JC, Goulis DG. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. *Int J Clin Pract*. 2016;70(12):967-977.
27. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. *Circulation*. 1993;87(4):1135-1141.
28. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. *J Am Coll Cardiol*. 2008;52(2):124-131.
29. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. *JAMA*. 2000;283(14):1845-1852.
30. Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. *Nat Genet*. 1995;9(4):424-431.
31. Zysow BR, Kausar K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. *Arterioscler Thromb Vasc Biol*. 1997;17(9):1741-1745.
32. Boffelli D, Zajchowski DA, Yang Z, Lawn RM. Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. *J Biol Chem*. 1999;274(22):15569-15574.
33. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low-density lipoprotein receptor. *J Biol Chem*. 2015;290(18):11649-11662.
34. Starr AE, Lemieux V, Noad J, et al. Beta-estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. *FEBS J*. 2015;282(14):2682-2696.
35. Hussain Y, Ding Q, Connelly PW, et al. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies. *Arterioscler Thromb Vasc Biol*. 2015;35(1):213-221.
36. Gaeta G, Lanero S, Barra S, et al. Sex hormones and lipoprotein(a) concentration. *Expert Opin Investig Drugs*. 2011;20(2):221-238.
37. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). *J Am Coll Cardiol*. 2013;62(17):1575-1579.
38. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365(24):2255-2267.
39. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med*. 2003;349(6):523-534.
40. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. *JAMA*. 1998;280(7):605-613.
41. Ferretti G, Bacchetti T, Simental-Mendia LE, Reiner Z, Banach M, Sahebkar A. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. *Cardiovasc Drugs Ther*. 2017;31(2):197-208.
42. Sahebkar A, Serban MC, Penson P, et al. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. *Drugs*. 2017;77(11):1187-1197.
43. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study. *Breast Cancer Res Treat*. 2012;136(3):769-776.
44. Kotani K, Sahebkar A, Serban C, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. *Atherosclerosis*. 2015;242(1):87-96.
45. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010;31(23):2844-2853.
46. Anderson TJ, Gregoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol*. 2016;32(11):1263-1282.
47. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016;37(39):2999-3058.
48. Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? *Prog Lipid Res*. 2017;68:57-82.
49. van Capelleve JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein(a). *J Lipid Res*. 2016;57:1612-8.
50. Boffa MB. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. *Curr Atheroscler Rep*. 2016;18(12):69.

Guest Editorial

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics – 2017 Update: A Report From the American Heart Association. *Circulation*. 2017;135(10):e146-e603.
2. Laslett LJ, Alagona P Jr, Clark BA III, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of

39. Viney NJ, van Capellevee JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet*. 2016;388(10057):2239-2253.
- EBM Tools for Practice**
- Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. *JAMA*. 2004;291(18):2243-2252.
 - Cholesterol Treatment Trialists. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*. 2015;385:1397-405.
 - Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from JUPITER and meta-analysis of women from primary prevention trials. *Circulation*. 2010;121:1069-1077.
 - Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomized controlled trials. *BMJ*. 2009;338:b2376.
 - Karmali KN, Goff DC, Ning, Hongyan, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. *J Am Coll Cardiol*. 2014;64:959-68.
 - Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <https://doi.org/10.1161/01.cir.0000437741.48606.98>
 - Circulation. 2013;01.cir.0000437741.48606.98
 - Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Executive Summary. *Jour Clin Lipid*. 2014;8(5):473-488.
 - Sniderman AD, Thanassoulis G, Williams K, Stat MS, Pencina M. Risk of Premature Cardiovascular Disease vs. the Number of Premature Cardiovascular Events. Letter. *JAMA Cardiology*. 2016;1(4):492-93.
 - Soran H, Schofield JD, Durrington PN. The importance of considering LDL-cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. *Curr Opin Lipidol*. 2014;25:239-46.
 - Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. *Eur Heart J*. 2015;36:2975-2983. doi: 10.1093/eurheartj/ehv340.
 - Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670-1681.
 - Thanassoulis G, Williams K, Altabelli KK, Pencina MJ, Cannon CP, Sniderman AD. Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease. *Circulation*. 2016;133:1574-1581.
 - Thanassoulis (private communication).
 - Shah SH, Arnett D, Houser SR, et al. Opportunities for the cardiovascular community in the precision medicine initiative. *Circulation*. 2016;133:226-31.
 - Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: An opportunity to harmonize guidelines – Viewpoint. *JAMA Cardiology*. Published online Aug. 9, 2017.
- Lipid Luminations**
- Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. *Circulation*. 1987;75(6):1102.
 - Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. *Ann Intern Med*. 2000;133(12):933.
 - Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. *N Engl J Med*. 1987;316(4):173.
 - Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321.
 - Final Recommendation Statement: Menopausal Hormone Therapy: Preventive Medication. U.S. Preventive Services Task Force. <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/menopausal-hormone-therapy-preventive-medication> (accessed December 2017)
 - Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. *JAMA*. 2017;318(10):927-38.
 - Cobin RH, Goodman NF. AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause-2017 update. *Endocr Pract*. 2017;23 (7): 869-880.
 - Baber RJ, Panay N, Fenton A. the IMS Writing Group (2016). 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016;19(2),109-150.
 - Premarin (conjugated estrogens) Tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2014.
- Specialty Corner**
- Nelson HD. Menopause. *Lancet*. 2008;371:760-770.
 - Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-333.
 - Nelson HD, Humphrey L, Nygren P, et al. Postmenopausal Hormone Replacement Therapy. *JAMA*. 2002;288(7):872-881.
 - Brisdelle [package insert]. Miami, Fla.: Noven Therapeutics, LLC; 2013.
 - Orleans R, Li L, Kim MJ, et al. FDA Approval of Paroxetine for Menopausal Hot Flashes. *N Engl J Med*. 2014;370:1777-1779.
 - Dalal PK, Agarwal M. Postmenopausal syndrome. *Indian Journal of Psychiatry*. 2015;57(Suppl 2):S222-S232. doi:10.4103/0019-5545.161483.
 - Reddy S, Warner H, Guttuso T, et al. Gabapentin, Estrogen, and Placebo for Treating Hot Flashes: A Randomized Controlled Trial. *Obstetrics & Gynecology*; 2006;108(1):41-48.
 - Moore TR, et al. Review of Efficacy of Complementary and Alternative Medicine Treatments for Menopausal Symptoms. *J Midwifery Womens Health*. 2017 May; 62(3):286-297.
 - Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent: Successful therapy with cimicifuga mono-extract. *Die Medizinische Welt*. 1985;36:871-874.
 - Liske E, Hanggi W, Henneicke-Von Zepelin HH, et al. Physiological investigation of a unique extract of black cohosh (*cimicifugae racemosae rhizoma*): A 6-month clinical study demonstrates no systemic estrogenic effect. *J Womens Health Gen Based Med*. 2002;11:163-74.
 - Ruhlen RL, Sun GY, Sauter ER. Black Cohosh: Insights into its Mechanism(s) of Action. *Integr Med Insights*. 2008 Aug;3:21-32.
 - The North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. *Menopause*. 2015; 22(11): 1-18.
 - Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. *Menopause*. 2008;15:628-638.
 - Files JA, Ko MG, Pruthi S. Bioidentical Hormone Therapy. *Mayo Clin Proc*. 2011 Jul; 86(7):673-680.
 - Santoro N, Braunstein GD, Butts CL, et al. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. *JCEM*. 2016 Apr;101(4):1318-1343.
 - Stuenkel CA, Manson JE. Compounded Bioidentical Hormone Therapy. Does the Regulatory Double Standard Harm Women? *JAMA Intern Med*. 2017;177(12):1719-1720
- Practical Pearls**
- Primary hyperlipidemias. J Davignon, R Dufour. Clinical Publishing, Oxford, UK, 2007.
 - ApoB app. Available at play.google.com and at itunes.apple.com
 - deGraaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. *Nat Clin Pract Endocrinol Metab*. 2008 Nov;4(11):608-18.
 - Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. *The J Clin Lipidol and Metabolism*. 2012;9(9):2969-2989. doi:10.1210/jc.2011-3213
 - Bays HE, Jones PH, et al. National Lipid Association annual summary of clinical Lipidology 2016. *J Clin Lipidol* 2016;10:S1-S43.
 - Bellamy L, Casa JP, Hingorani AD, Williams D. Pre-eclampsia and risk of cardiovascular disease and cancer later in life: systematic review and meta-analysis. *BMJ* 2007;335(7627):974.
 - Bellamy L, Casa JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational DM: systematic review and meta-analysis. *Lancet*. 2009;373(9677):1735.
 - Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centred management of dyslipidemia: part 1 – full report. *J Clin Lipidol*. 2015;9(6):S1-S122.e.1.
- Case Study**
- Nordestegaard BG Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. *European Heart Journal*. 2013;34(45):3478-3490.
 - McMahan CA, Gidding SS, Viihari JS, et al. Association of pathobiologic determinants of atherosclerosis in youth risk score and 15-year change in risk score with carotid artery intima-media thickness in young adults (from the Cardiovascular Risk in Young Finns Study). *Am J Cardiol*. 2007;100(7):1124-1129.
 - Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents; National Heart, Lung and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(Suppl. 5),S213-S256.
 - McNeal CJ, Underland L, Wilson DP, Blackett, PR. Pediatric Lipid Screening. *J Clin Lipidology*. 2013;8(4):425-436.
 - Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*. 2011;5(Suppl. 3):S30-S37.
 - Martin AC, Coakley J, Forbes DA, Sullivan DR, Watts GF. Familial hypercholesterolemia in children and adolescents: a new pediatric model of care. *J Paediatr Child Health*. 2013;49:E263-E272.
 - Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 2007;27:1803-1810.
 - Magnussen CG, Venn A, Thomson R, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. *J Am Coll Cardiol*. 2009;53(10):860-869.
 - de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2002;40(12),2117-121.
 - Robinson JG, Gidding S. Curing atherosclerosis should be the next major cardiovascular prevention goal. *J Am Coll Cardiol*. 2014;63:2779-2785.
 - Mosca LJ. Optimal Management of Cholesterol Levels and the Prevention of Heart Coronary Heart Disease in Women. *Am Fam Physician*. 2002;65(2):217-227.
 - Pearson TA, Laurant I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (LTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. *Arch Intern Med*. 2000;160:459-467.
 - Mora S, Glynn, R.J, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin. *Circulation*. 2010;121(9):1069-1077.
 - Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the

- prevention of recurrent cardiovascular events: A sex-based meta-analysis. *Arch Intern Med.* 2012 Jun 25;172:909.
15. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomized trials. *Lancet.* 2015; 385:1368-1374.1
 16. Mombelli R, Mombelli G. Familial Hypercholesterolemia and Pregnancy: Risk and Management. *Obstetrics & Gynaecology Cases - Reviews.* 2015;2:8.
 17. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low-density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. *J Clin Invest.* 1997 Dec 1;100(11):2680-90.
 18. Van der Graaf A, Vissers MN, Gaudet D, et al. Dyslipidemia of mothers with familial hypercholesterolemia deteriorates lipids in adult offspring. *Arterioscler Thromb Vasc Biol.* 2010 Dec;30(12):2673-7.
 19. Thorogood M, Seed M, De Mott K, Guideline Development Group. Management of fertility in women with familial hypercholesterolemia: summary of NICE guidance. *Br J Obstet Gynaecol.* 2009;116:478-479.
 20. Goldberg A, Hopkins P, Toth P, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol.* 2011 Jun;5(3 Suppl):S1-8.
 21. Kusters DM, Hassani Lahsinoui H, van de Post JA, et al. Statin use during pregnancy: a systematic review and meta-analysis. *Expert Rev Cardiovasc Ther.* 2012 Mar;10(3):363-78.
 22. Cashin-Hemphill L, Noone M, Abbott JF, et al. Low-density lipoprotein apheresis therapy during pregnancy. *Am J Cardiol.* 2000 Nov 15;86(10):1160, A10.
 23. Aneeda S, Mura S, Marcello C, Pintus P. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. *Transfus Apher Sci.* 2011 Feb;44(1):21-4.
 24. Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. *Atherosclerosis.* 2008 Jun;198(2):247-55.
 25. Huy P, Pham MD, Joseph Schwartz MD. LDL Apheresis. *Transfusion Medicine and Hemostasis* (Second Edition). 2013.
 26. Wong E, Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. *P T.* 2014 Feb;39(2):119-22.

National Lipid Association

SELF-ASSESSMENT PROGRAM



completely revised web-based
comprehensive earn CME/CE
robust content evidenced-based

4th Edition

Module 1: The Science of Lipidology: Lipid Metabolism, Pathogenesis of Atherosclerosis and Genetic Disorders

Module 2: Evidence-based Medicine and Statistics: ASCVD Risk Assessment and Risk Indicators and Subclinical Atherosclerosis Detection

Module 3: Contemporary Management of Dyslipidemia: Lipid Guidelines

Module 4: Contemporary Management of Dyslipidemia: Lifestyle Therapy

Module 5: Contemporary Management of Dyslipidemia: Pharmacologic Therapy

Order today at lipid.org/nlasap



CME credit provided by the National Lipid Association

These activities have been approved for *AMA PRA CATEGORY 1 CREDIT™*
These activities are eligible for CDR credit.



CE credit provided by Postgraduate Institute for Medicine.

These activities are eligible for ACPE and ANCC credit, see final CE activity announcement for specific details. Full accreditation information is available at <https://www.lipid.org/nlasap>